Limerick is developing compounds to minimize toxic side effects at non-targeted vulnerable organs and tissue while maintaining or enhancing a drug's desired effects. In the monotherapy setting, the company is developing novel compounds that target the treatment of metabolic diseases such as hypercholesteremia and hyperglycemia.